Revolution Medicines is conducting phase 3 trials for daraxonrasib, targeting active KRAS mutations, with promising results in preclinical and clinical studies. RAS(ON) therapies aim to address ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS-G12D,” Dr. Arbour says. “What we saw in these patients is dramatically ...

Potential regulatory submission timelines may create pressure on the ... company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Notably, FGFR2 expression in murine precancerous lesions correlated with an increase in mutant KRAS signaling. Results showed that FGFR2 gene deletion led to significantly fewer precancerous ...

Cold Spring Harbor Laboratory Experts at the Cold Spring Harbor Laboratory have discovered a way to block threatening biological factors associated with another critical protein called KRAS.